Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

Jonathan Trujillo(University of Chicago), Thomas F. Gajewski(University of Chicago)

Journal for ImmunoTherapy of Cancer

November 8, 2019

10.1186/s40425-019-0780-0

Cited by 157

Related Papers

Impact of oncogenic pathways on evasion of antitumour immune responses

|Nature reviews. Cancer|2018|652

Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

|Journal of Clinical Oncology|2013|594

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

|Journal for ImmunoTherapy of Cancer|2014|543

Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma

|JAMA|2014|429

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

|Journal of Clinical Oncology|2018|382